erasca.com (ERAS) - Cash per Share

Erasca Oncology - graphic logo of issuer ERAS

Analyzing the cash per share dynamics on GURU.Markets, we find that the value of 1.83 corresponds to the current metric. This indicator for Erasca, Inc. (ERAS) is explained by a lack of sales due to the therapy development stage and active resource expenditure on R&D. The company's success relies on regulatory approvals and test results. The brand's scientific authority supports cautious investor optimism.

Erasca Corp (ERAS) - Cash per Share from 07/04/2022 to 11/20/2026

Comprehensive metric breakdowns and analytics for Erasca Inc (ERAS)

- stock value and consensus price forecast:
- cash availability and cash flow indicators:
General company analysis:Erasca, Inc.
Product sample of Erasca

For Erasca, Inc. (ERAS), which is developing innovative oncology drugs in the clinical trial stage, liquidity reserves determine the autonomous funding horizon prior to product commercialization. The current cash per share trend on the GURU.Markets platform reflects the volume of free resources available to each shareholder, allowing for an assessment of the issuer's financial stability and the risk of capital stagnation in the absence of new investments.

Key competitors

Cash Funds per Single Share ONC (BeiGene Corp)|Cash per Single Share HALO (Halozyme Therapeutics, Inc.)|Cash per Share Revolution Medicines, Inc. (RVMD)|Cash per Share AAPG (ascentage.com)|CG Oncology Inc (CGON) - Cash on Hand per Share|URGN - Cash Funds per Share|Bicara Bio - Cash Calculated per Single Share|PSNL: Cash per Share|DCTH - Cash Funds Calculated per Share|YMAB (Y-mAbs Corp) - Cash per Share|Cash per Single Share Aura Biosciences (AURA)|Cash Funds per Share Candel Therapeutics Inc. (CADL)|Cash per Single Share Accuray, Inc. ARAY|Cash Funds per Share sellaslifesciences.com SLS|Amount of Cash per Share ACTU|CTOR - Cash Funds per Share|Cash Funds Calculated per Share tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Cash Funds per Share|FATE: Cash Calculated per Single Share|WHWK (Aadi Bioscience, Inc.) - Cash per Share|TCRX (TScan Therapeutics) - Cash Calculated per Single Share|Cash Funds per Share Champions Oncology (CSBR)|Cash Funds Calculated per Share XBiotech USA|Cash Funds per Share CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Cash on Hand per Share|RADX - Cash Funds per Share|ARTV - Cash per Share|Adlai Nortye Ltd (ANL) - Cash Funds per Share|Veru Pharma - Amount of Cash per Share|Cash Funds per Share Tempest Therapeutics Corp|Cash Funds per Single Share XLO (Xilio Therapeutics, Inc.)|Cash per Share RENB|MURA (Mural Oncology) - Amount of Cash per Share|Cash per Share KAPA (Kairos Pharma Ltd)|OKUR: Cash Funds per Single Share|GDTC: Cash per Single Share|CRIS - Cash per Share|APLM: Cash per Share|Cash on Hand per Share tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Cash per Share|Cash per Share Genprex Inc.|Cash per Share CLDI|Cash per Single Share Sunshine Biopharma, Inc. SBFM|Cash per Share XBIO (Xenetic Biosciences)|Amount of Cash per Share SLRX|PPBT - Cash Funds per Share|AONC (aoncology.com) - Cash Funds per Single Share|BGNE: Cash per Share|Checkpoint Therapeutics Inc (CKPT) - Cash per Share|ELEV (Elevation Oncology Inc.) - Cash per Share|icadmed.com (ICAD) - Cash Funds Calculated per Share|Cash per Share IKNA|NTBL (Notable Labs) - Amount of Cash per Share|Cash per Share VIRX (Viracta Therapeutics)|Cash Funds Calculated per Share MorphoSys AG (MOR)|NAYA Biosciences Corp - Cash per Share|Cash on Hand per Share ascentage.com